Skip to main content
Article thumbnail
Location of Repository

Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]

By Sean P Curtis, Barry Bockow, Chester Fisher, Joseph Olaleye, Amy Compton, Amy T Ko and Alise S Reicin
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2001). BJ: Renal effects of cox-2-selective inhibitors.
    2. (1993). Brater DC: Renal toxicity of the nonsteroidal antiinflammatory drugs. Annu Rev Pharmacol Toxicol
    3. (2005). Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
    4. Clinical Features of Osteoarthritis.
    5. (2005). CS: Tolerability and effectiveness of etoricoxib compared to diclofenac sodium in patients with osteoarthritis: a randomized controlled study (EDGE trial). Arthritis Rheum
    6. (1996). Development and progression of osteoarthritis.
    7. (2004). Drugs Today (Barc )
    8. (2003). F: Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther
    9. (2002). Gertz BJ: Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology
    10. (2000). GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA
    11. (2005). JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    12. (2001). Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol
    13. (2003). Reicin AS: Etoricoxib cardiovascular safety summary. Circulation
    14. (2004). Reicin AS: Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther
    15. (2004). S: GI-related treatment discontinuations with etoricoxib compared with nonselective cyclooxygenase inhibitors (NSAIDS) and placebo. Ann Rheum Dis
    16. (2000). TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.